N'-[2-fluoro-5-(trifluoromethyl)phenyl]-N-methyl-urea | 33251-67-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N'-[2-fluoro-5-(trifluoromethyl)phenyl]-N-methyl-urea
• 英文别名: 1-[2-Fluoro-5-(trifluoromethyl)phenyl]-3-methylurea
• CAS: 33251-67-1
• 化学式: C₉H₈F₄N₂O
• 分子量: 236.169
• InChiKey: PCKZHQPQVHFDAS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  16
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  41.1
• 氢给体数：
  2
• 氢受体数：
  5

文献信息

• [EN] INHIBITORS OF PROTEIN TYROSINE KINASE ACTIVITY<br/>[FR] INHIBITEURS DE L'ACTIVITÉ PROTÉINE TYROSINE KINASE
  申请人：METHYLGENE INC

  公开号：WO2009026717A1

  公开（公告）日：2009-03-05

  The invention relates to compounds of Formula (I) and their use for inhibiting protein tyrosine kinase activity In Formula (I), the group M is thieno[3,2,b]pyridinyl as shown, and the group D is a ring or ring system, and the groups Z, Ar, and G are as defined herein The invention relates particularly to compounds that inhibit the protein tyrosine kinase activity of growth factor receptors, resulting in the inhibition of receptor signalling, for example, the inhibition of VEGF receptor signalling and HGF receptor signalling The invention also provides compositions and methods for treating cell proliferative diseases and conditions, such as cancer, and for treating ophthalmic diseases, including age-related macular degeneration (AMD) and diabetic retinopathy (DR).

  该发明涉及式（I）化合物及其用于抑制蛋白酪氨酸激酶活性。在式（I）中，基团M为所示的噻吩[3,2,b]吡啶基团，基团D是一个环或环系统，基团Z、Ar和G如本文所定义。该发明特别涉及抑制生长因子受体的蛋白酪氨酸激酶活性的化合物，从而抑制受体信号传导，例如抑制VEGF受体信号传导和HGF受体信号传导。该发明还提供用于治疗细胞增殖性疾病和病症的组合物和方法，例如癌症，并用于治疗眼科疾病，包括老年性黄斑变性（AMD）和糖尿病性视网膜病变（DR）。
• [EN] PROCESSES AND INTERMEDIATES FOR PREPARING FUSED HETEROCYCLIC KINASE INHIBITORS<br/>[FR] PROCÉDÉS ET INTERMÉDIAIRES DE PRÉPARATION D'INHIBITEURS DE KINASES HÉTÉROCYCLIQUES FUSIONNÉS
  申请人：METHYLGENE INC

  公开号：WO2009026720A1

  公开（公告）日：2009-03-05

  The invention relates to processes and intermediates for manufacturing fused heterocyclic-type kinase inhibitor compounds, such as thienopyridine-based compounds, and to processes and intermediates for preparing intermediates that are useful in the manufacture of fused heterocyclic-type kinase inhibitor compounds, particularly at an industrial level The processes are aimed at ultimately forming compounds of the formula (A) where M is thieno[3,2,b]pyridinyl as shown, the group D is a ring or ring system, preferably pyridine, and the group Z, Ar, and G are as defined herein Such compounds can act to inhibit the protein tyrosine kinase activity of growth factor receptors, resulting in the inhibition of receptor signalling, for example, the inhibition of VEGF receptor signalling and HGF receptor signalling.

  该发明涉及制造熔合杂环型激酶抑制剂化合物的过程和中间体，例如噻吩吡啶基化合物，并涉及制备在制造熔合杂环型激酶抑制剂化合物时有用的中间体的过程和中间体，特别是在工业水平上。这些过程旨在最终形成化合物的结构式（A），其中M是如所示的噻吩[3,2,b]吡啶基，基团D是一个环或环系统，最好是吡啶，基团Z、Ar和G如本文中所定义。这些化合物可以作用于抑制生长因子受体的蛋白酪氨酸激酶活性，从而抑制受体信号传导，例如抑制VEGF受体信号传导和HGF受体信号传导。
• SUBSTITUTE ISOQUINOLINES USEFUL IN THE TREATMENT OF DISEASES SUCH AS CANCER AND ATHEROSCLEROSIS
  申请人：Washio Yoshiaki

  公开号：US20090291949A1

  公开（公告）日：2009-11-26

  A compound of Formula (I): or a salt or solvate thereof, wherein: One of R 1 and R 2 is H and the other represents —NHCONHR 4 , wherein R 4 represents a phenyl or naphthyl group which may be optionally substituted by one or more substituents independently selected from —C 1-6 alkyl, —C 1-6 haloalkyl, halogen, C 1-6 alkoxy, C 1-6 haloalkoxy, OH, NO 2 , C 3-7 cycloalkyl, indanyl, or R 4 together with the NH to which it is bonded forms a morpholino group; and R 3 is H or NHR 5 wherein R 5 is H, -quinolinyl or -isoquinolinyl, —(CONH) p phenyl wherein p is 0 or 1 and the phenyl is optionally substituted by one or more substituents independently selected from halogen, —C 1-6 alkyl, —C 1-6 haloalkyl, -morpholino, —SO 2 NH 2 , and methyl substituted benzothiazole.

  化合物的化学式为（I）或其盐或溶剂化合物，其中： R1和R2中的一个是H，另一个表示为—NHCONHR4，其中R4表示苯基或萘基，可以选择地由一个或多个取代基独立选择从—C1-6烷基，—C1-6卤代烷基，卤素，C1-6烷氧基，C1-6卤代烷氧基，OH，NO2，C3-7环烷基，吲哚基或R4与其连接的NH形成吗啡环基；而R3是H或NHR5，其中R5是H，-喹啉基或-异喹啉基，—（CONH）pphenyl，其中p为0或1，苯基可以选择地由一个或多个取代基独立选择从卤素，—C1-6烷基，—C1-6卤代烷基，-吗啡环基，—SO2NH2和甲基取代苯并噻唑基。
• Processes and intermediates for preparing fused heterocyclic kinase inhibitors
  申请人：Raeppel Franck

  公开号：US20090286984A1

  公开（公告）日：2009-11-19

  This invention relates to processes and intermediates for manufacturing fused heterocyclic-type kinase inhibitor compounds, such as thienopyridine-based compounds, and to processes and intermediates for preparing intermediates that are useful in the manufacture of fused heterocyclic-type kinase inhibitor compounds, such as thienopyridine-based compounds, particularly at an industrial level.

  本发明涉及用于制造融合杂环型激酶抑制剂化合物的过程和中间体，例如噻吩并吡啶基化合物，并涉及用于制备在制造融合杂环型激酶抑制剂化合物，例如噻吩并吡啶基化合物中有用的中间体的过程和中间体，特别是在工业水平上。
• PROCESSES AND INTERMEDIATES FOR PREPARING FUSED HETEROCYCLIC KINASE INHIBITORS
  申请人：Raeppel Franck

  公开号：US20120095234A1

  公开（公告）日：2012-04-19

  This invention relates to processes and intermediates for manufacturing fused heterocyclic-type kinase inhibitor compounds, such as thienopyridine-based compounds, and to processes and intermediates for preparing intermediates that are useful in the manufacture of fused heterocyclic-type kinase inhibitor compounds, such as thienopyridine-based compounds, particularly at an industrial level.

  本发明涉及制造融合杂环型激酶抑制剂化合物（例如基于噻吩并吡啶的化合物）的过程和中间体，以及制备有用于制造融合杂环型激酶抑制剂化合物（例如基于噻吩并吡啶的化合物）的中间体的过程和中间体，特别是在工业水平上。